NEWS BIOCON

1.

Biocon adds heft to research services arm

Syngene works with 16 of the top 20 pharma companies across the globe .As
Biocon holds back the public listing of its research services arm, Syngene, the
company is strengthening the division by aggressively pursuing global majors to
build a larger, attractive clientele and a bigger workforce. Syngene International
Ltd, a subsidiary of Biocon, tied up with Baxter International Inc, a US-based
pharmaceutical company to jointly establish a research centre within the Syngene
premises in Bangalore.
2.

Biocon Q3 net up 14 per cent at Rs 104.99 crore...

Bangalore-based biotech major Biocon Ltd reported 14.41 per cent increase in its
consolidated net profit for the third quarter ended December 31, 2013 at Rs 104.99
crore. The company had posted a consolidated net profit of Rs 91.76 crore in the
same quarter last fiscal. Consolidated net sales during the quarter under review
stood at Rs 701.16 crore as against Rs 634.22 crore in the year-ago period.
3. Biocon's Kiran Mazumdar-Shaw to receive 2014

Othmer Gold
Bio-tech firm Biocon Ltd ,Chairperson and Managing Director Kiran Mazumdar Shaw, will be conferred the 2014 Othmer Gold Medal, the top award of US-based
Chemical Heritage Foundation.

4. Biocon inks pact with Advaxis for novel cancer

immunotherapy 'ADXS-HPV'
Biocon and Advaxis Inc., a leader in the next generation of cancer
immunotherapies have entered into an exclusive licensing agreement for codevelopment and commercialization of ADXS-HPV, a novel cancer
immunotherapy for the treatment of human papillomavirus (HPV)-associated
cervical cancer in women, for India and key emerging markets.

5. Biocon to tackle glaucoma through global tie-up

Biocon has expanded its therapeutic portfolio with the addition of ophthalmology
through a licensing and collaborative partnership with the US-based Quark
Pharmaceuticals. With revenues topping Rs 2,500 crore, Biocon is aiming to cross
$1 billion in revenues by the end of fiscal 2017-18, fuelled by development of
small molecules, biosimilars, branded formulations, novel molecules, and research
services.
6. Biocon, Quark tie up to develop eye drug
Biocon Ltd, and Quark Pharmaceuticals, Inc, a global player in the discovery and
development of therapeutics based on siRNA (small interfering)-RNA, have
entered into a licensing and collaboration pact for developing a range of siRNAbased novel therapeutics. The financial terms of the pact were not disclosed. This
arrangement will allow Biocon to co-develop, manufacture and commercialize
QPI-1007, a novel siRNA drug candidate for ophthalmic conditions, for India and
other key markets.
7. Biocon setting up Biotech Training Institute in

Bangalore
Biocon is setting up an institute in Bangalore to train graduates in skills required
for finding employment in the fast-growing biotechnology industry. Starting
January 2014, the institute will offer a 16-week certificate-programme in
partnership with California-based Keck Graduate Institute
The programme-with a course fee of Rs 6 lakh-will cover areas including
molecular biotechnology, pharmaceutical development, bio-pharmaceutical quality
assurance and introduction to US FDA and European Laws.
India's biotech sector currently is valued at $11billion, growing at an average
annual rate of more than 20% over the past ten years. Every year roughly 40,000
biotech students graduate from 725 institutions.